Follow The Filings

URGN position history

The shares of Urogen Pharma (URGN) that Palo Alto Investors LP reported in each quarter’s 13F.

Equity, COM

Shares held by quarter

New Add Reduce Exit

  1. 2021 Q3: 24,500 shares, $412K, 0.02% of portfolio
  2. 2021 Q4: 24,500 shares, $233K, 0.01% of portfolio
  3. 2022 Q1: 24,500 shares, $213K, 0.02% of portfolio
  4. 2022 Q2: 24,500 shares, $201K, 0.02% of portfolio
  5. 2022 Q3: 24,500 shares, $204K, 0.02% of portfolio
  6. 2022 Q4: 24,500 shares, $217K, 0.02% of portfolio
  7. 2023 Q1: 24,500 shares, $226K, 0.02% of portfolio
  8. 2023 Q2: 24,500 shares, $254K, 0.02% of portfolio
  9. 2023 Q3: 24,500 shares, $343K, 0.03% of portfolio
  10. 2023 Q4: 49,000 shares, $735K, 0.07% of portfolio, Add +100.0%
  11. 2024 Q1: 24,500 shares, $368K, 0.04% of portfolio, Reduce −50.0%
  12. 2024 Q2: 24,500 shares, $411K, 0.05% of portfolio
  13. 2024 Q3: 24,500 shares, $311K, 0.04% of portfolio
  14. 2024 Q4: 24,500 shares, $261K, 0.04% of portfolio
  15. 2025 Q1: 24,500 shares, $271K, 0.05% of portfolio
  16. 2025 Q2: 24,500 shares, $336K, 0.07% of portfolio
  17. 2025 Q3: 24,500 shares, $489K, 0.09% of portfolio
  18. 2025 Q4: 24,500 shares, $574K, 0.08% of portfolio
  19. 2026 Q1: 24,500 shares, $441K, 0.07% of portfolio
  20. 2026 Q2: 24,500 shares, $902K, 0.12% of portfolio
Holdings date Value % of holdings Shares Filing date All 13F holders